Revolution Medicines (NASDAQ:RVMD) CFO Sells 20,000 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jack Anders also recently made the following trade(s):

• On Tuesday, June 16th, Jack Anders sold 2,722 shares of Revolution Medicines stock. The stock was sold at an average price of $156.12, for a total transaction of $424,958.64.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD traded up $3.91 during trading on Friday, reaching $182.08. The stock had a trading volume of 9,539,559 shares, compared to its average volume of 3,377,479. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The stock has a market capitalization of $38.71 billion, a PE ratio of -25.75 and a beta of 1.40. The business’s 50-day moving average price is $151.19 and its 200 day moving average price is $116.22. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $184.39.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter in the prior year, the business posted ($1.13) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Analysts Set New Price Targets

RVMD has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Revolution Medicines from $169.00 to $195.00 and gave the company a “buy” rating in a report on Monday, June 1st. Jefferies Financial Group assumed coverage on Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating on the stock. Truist Financial assumed coverage on Revolution Medicines in a research report on Monday, May 18th. They set a “buy” rating and a $179.00 target price for the company. Piper Sandler raised their price target on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Sanford C. Bernstein initiated coverage on Revolution Medicines in a research report on Thursday, May 21st. They issued a “market perform” rating and a $151.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $123.72.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Revolution Medicines by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after buying an additional 1,056,792 shares during the period. Farallon Capital Management LLC increased its stake in shares of Revolution Medicines by 2.1% in the 3rd quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after acquiring an additional 300,000 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Revolution Medicines by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after acquiring an additional 947,448 shares during the period. Baker BROS. Advisors LP boosted its stake in Revolution Medicines by 1.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock worth $441,565,000 after acquiring an additional 90,385 shares during the last quarter. Finally, Nextech Invest Ltd. boosted its stake in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.